• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » CSA Medical names VP of emerging therapies

CSA Medical names VP of emerging therapies

September 13, 2011 By MassDevice Contributors Network

BALTIMORE, Sept. 12, 2011 /PRNewswire/ — CSA Medical, Inc. (www.CSAmedical.com), the leading developer of novel Spray Cryotherapy devices that flash freeze and treat diseased tissue inside the body, today announced the appointment of Wendelin Maners to the newly created position of Vice President, Emerging Therapies. In this role Maners will be responsible for the development of new therapeutic applications for the company’s Spray Cryotherapy technology.

"Wendelin has an impressive track record of working closely with executive teams and applying a thoughtful, analytical and collaborative approach to building new markets and solidifying current platforms," said Bill Floyd, CEO and president of CSA Medical. "Throughout her career she has also executed over $3 billion in transactions that provided product and therapy diversification to maximize shareholder value. We are thrilled to have her join our team."

Maners brings to CSA Medical more than 18 years of global medical device experience focused on acquisition, licensing and marketing emerging technologies. Most recently she served as Vice President, Strategy and Business Development at Boston Scientific Corporation where she developed and executed acquisition and investment strategies in the Neuromodulation and Electrophysiology markets, as well as new markets for the company. During her tenure at Boston Scientific, Maners’ focus also included entering the implantable microelectronics space with the acquisition of Advanced Bionics and leading the due diligence and negotiations for the acquisition of CryoCor, an endocardial cryo ablation technology for atrial fibrillation. From 2000-2003, Ms. Maners worked as an investment banker with Barrington Associates (Wells Fargo Securities). Previously she held marketing positions focused on entering new markets with Boston Scientific’s urology and interventional neuroradiology divisions. Maners holds a bachelor of science degree in Business Administration from the University of Southern CaliforniaMarshall School of Business.

"I believe that CSA Medical’s Spray Cryotherapy device has tremendous potential to treat multiple disease states, drastically improve patient outcomes and reduce the cost of healthcare," said Maners. "I look forward to working with my colleagues to realize the fullest potential for this innovative technology."

About CSA Medical

CSA Medical, Inc. develops and manufactures a proprietary therapeutic interventional platform, the Spray Cryotherapy System, comprised of a device, specialty catheters and agent that allows delivery of therapeutic doses of a cryogen to flash freeze and destroy diseased tissue inside the body. The Company is the first to harness the power of extreme cold (-196 C) liquid nitrogen therapeutic energy delivery inside the body. To learn more, please visit www.CSAmedical.com.

SOURCE CSA Medical, Inc.

Filed Under: Uncategorized Tagged With: CSA Medical Inc., Personnel Moves

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy